Advertisement
Australia markets closed
  • ALL ORDS

    7,974.80
    -27.70 (-0.35%)
     
  • ASX 200

    7,724.30
    -25.40 (-0.33%)
     
  • AUD/USD

    0.6613
    -0.0025 (-0.37%)
     
  • OIL

    78.29
    -0.33 (-0.42%)
     
  • GOLD

    2,343.30
    +25.30 (+1.09%)
     
  • Bitcoin AUD

    101,067.97
    +162.35 (+0.16%)
     
  • CMC Crypto 200

    1,419.32
    +1.44 (+0.10%)
     
  • AUD/EUR

    0.6180
    +0.0007 (+0.12%)
     
  • AUD/NZD

    1.0772
    +0.0020 (+0.18%)
     
  • NZX 50

    11,864.89
    -7.75 (-0.07%)
     
  • NASDAQ

    19,583.06
    +6.14 (+0.03%)
     
  • FTSE

    8,152.15
    -11.52 (-0.14%)
     
  • Dow Jones

    38,516.65
    -130.45 (-0.34%)
     
  • DAX

    18,017.31
    -248.37 (-1.36%)
     
  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

Corcept Therapeutics First Quarter 2024 Earnings: Beats Expectations

Corcept Therapeutics (NASDAQ:CORT) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$146.8m (up 39% from 1Q 2023).

  • Net income: US$27.5m (up 74% from 1Q 2023).

  • Profit margin: 19% (up from 15% in 1Q 2023). The increase in margin was driven by higher revenue.

  • EPS: US$0.27 (up from US$0.15 in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Corcept Therapeutics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 4.0%. Earnings per share (EPS) also surpassed analyst estimates by 14%.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in the US.

ADVERTISEMENT

Performance of the American Pharmaceuticals industry.

The company's shares are up 13% from a week ago.

Risk Analysis

Be aware that Corcept Therapeutics is showing 1 warning sign in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.